Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study to Evaluate the Efficacy and Safety of Fruquintinib in Combination With Paclitaxel Versus Paclitaxel Alone in Second Line Gastric Cancer

NCT03223376 is registered in ClinicalTrials.gov with Hutchison Medipharma Limited as lead sponsor.

NCT NCT03223376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03223376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study to Evaluate the Efficacy and Safety of Fruquintinib in Combination With Paclitaxel Versus Paclitaxel Alone in Second Line Gastric Cancer
Lead sponsor
Hutchison Medipharma Limited
Phase
Phase 3
Overall status
Completed
Start date
October 18, 2017
Completion date
September 9, 2022
Enrollment
703 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric cancer